EGFR and lung carcinoma: Owing to recent advances in translational research, the outcomes and quality of life of patients with lung cancer have greatly improved through the use of targeted therapy, including EGFR-, ALK-, and ROS1-targeting agents, compared with those of patients on conventional treatments, such as chemotherapy [3].